Company Filing History:
Years Active: 2012
Title: Mark David VanCleve: Innovator in Hepatitis B Detection
Introduction
Mark David VanCleve is a notable inventor based in Emeryville, CA (US). He has made significant contributions to the field of immunodiagnostics, particularly in the detection of hepatitis B virus (HBV) infection. His innovative work has led to the development of novel reagents and methods that enhance the accuracy of HBV detection.
Latest Patents
Mark David VanCleve holds a patent for "Rabbit monoclonal antibodies to hepatitis B surface antigens and methods of using the same." This patent includes reagents, methods, and immunodiagnostic test kits designed for the precise detection of HBV infection. The methods and kits utilize unique rabbit monoclonal antibodies that target HBV surface antigens (HBsAg) with mutations in the 'a' determinant region of HBsAg. He has 1 patent to his name.
Career Highlights
Mark is currently associated with Novartis Vaccines & Diagnostics GmbH, where he continues to work on advancing diagnostic technologies. His role at Novartis has allowed him to contribute to the development of innovative solutions in the healthcare sector.
Collaborations
Throughout his career, Mark has collaborated with esteemed colleagues, including David Y Chien and Yiu-Lian Fong. These collaborations have further enriched his research and development efforts in the field of immunodiagnostics.
Conclusion
Mark David VanCleve's contributions to hepatitis B detection through innovative patenting and collaboration highlight his importance in the field of immunodiagnostics. His work continues to impact the healthcare industry positively.